References
Abadias M, Escriche M, Vaque A, Sust M, & Encina G (2013). Safety,
tolerability and pharmacokinetics of single and multiple doses of a
novel sigma-1 receptor antagonist in three randomized phase I studies.
Br J Clin Pharmacol 75: 103-117.
Abbas H, Borde P, Willars GB, Ferry DR, & Safrany ST (2020). Hazards of
using masking protocols when performing ligand binding assays: Lessons
from the sigma-1 and sigma-2 receptors. Front Pharmacol 11:309.
Oxaliplatin 5mg/mL summary of Product Characteristics.[Online] Available from
https://www.medicines.org.uk/emc/product/6088/smpc. [Accessed:
January 2021].
Alon A, Schmidt HR, Wood MD, Sahn JJ, Martin SF, & Kruse AC (2017).
Identification of the gene that codes for the sigma-2 receptor. Proc
Natl Acad Sci U S A 114: 7160-7165.
Bozdogan H (1987). Model selection and Akaike’s Information Criterion
(AIC): The gerneal theory and its analytical extensions. Psychometrika
52: 345-370.
Bravo-Caparros I, Perazzoli G, Yeste S, Cikes D, Baeyens JM, Cobos
EJ, et al. (2019). Sigma-1 receptor inhibition reduces
neuropathic pain induced by partial sciatic nerve transection in mice by
opioid-dependent and -independent mechanisms. Front Pharmacol
10: 613.
Bruna J, Videla S, Argyriou AA, Velasco R, Villoria J, Santos C,
et al. (2018). Efficacy of a novel sigma-1 receptor antagonist for
oxaliplatin-induced neuropathy: A randomized, double-blind,
placebo-controlled Phase IIa clinical trial. Neurotherapeutics
15: 178-189.
Brust P, Deuther-Conrad W, Lehmkuhl K, Jia H, & Wunsch B (2014).
Molecular imaging of sigma-1 receptors in vivo: current status and
perspectives. Curr Med Chem 21: 35-69.
Cipriano PW, Lee SW, Yoon D, Shen B, Tawfik VL, Curtin CM, et al.(2018). Successful treatment of chronic knee pain following localization
by a sigma-1 receptor radioligand and PET/MRI: a case report. J Pain Res
11: 2353-2357.
Colloca L, Ludman T, Bouhassira D, Baron R, Dickenson AH, Yarnitsky
D, et al. (2017). Neuropathic pain. Nat Rev Dis Primers
3: 17002.
Cunningham VJ, Rabiner EA, Slifstein M, Laruelle M, & Gunn RN (2010).
Measuring drug occupancy in the absence of a reference region: the
Lassen plot re-visited. J Cereb Blood Flow Metab 30: 46-50.
Curtis MJ, Alexander S, Cirino G, Docherty JR, George CH, Giembycz
MA, et al. (2018). Experimental design and analysis and their
reporting II: updated and simplified guidance for authors and peer
reviewers. Br J Pharmacol 175: 987-993.
Davis MP (2015). Sigma-1 receptors and animal studies centered on pain
and analgesia. Expert Opin Drug Discov 10: 885-900.
Clinical trial results: An exploratory, randomized, double blind,
placebo controlled, parallel groups Phase II clinical trial to evaluate
the efficacy and safety of E-52862 (400 mg) by oral route, in patients
with post-surgical neuropathic pain. [Online] Available from
https://www.clinicaltrialsregister.eu/ctr-search/trial/2012-000402-30/results.
[Accessed: January 2021].
Grabner G, Janke AL, Budge MM, Smith D, Pruessner J, & Collins DL
(2006). Symmetric atlasing and model based segmentation: an application
to the hippocampus in older adults. Med Image Comput Comput Assist
Interv 9: 58-66.
Gris G, Portillo-Salido E, Aubel B, Darbaky Y, Deseure K, Vela JM,
et al. (2016). The selective sigma-1 receptor antagonist E-52862
attenuates neuropathic pain of different aetiology in rats. Sci Rep
6: 24591.
Hou S, Huh B, Kim HK, Kim K-H, & Abdi S (2018). Treatment of
chemotherpy-induced peripheral neuropathy: Systematic review and
recommendations. Pain Physician 21: 571-592.
Ichise M, Toyama H, Innis RB, & Carson RE (2002). Strategies to improve
neuroreceptor parameter estimation by linear regression analysis. J
Cereb Blood Flow Metab 22: 1271-1281.
Innis RB, Cunningham VJ, Delforge J, Fujita M, Gjedde A, Gunn RN,
et al. (2007). Consensus nomenclature for in vivo imaging of
reversibly binding radioligands. J Cereb Blood Flow Metab 27:1533-1539.
Ishikawa M, Ishiwata K, Ishii K, Kimura Y, Sakata M, Naganawa M,
et al. (2007). High occupancy of sigma-1 receptors in the human brain
after single oral administration of fluvoxamine: a positron emission
tomography study using [11C]SA4503. Biol Psychiatry 62:878-883.
Ishiwata K, Oda K, Sakata M, Kimura Y, Kawamura K, Oda K, et al.(2006). A feasibility study of [11C]SA4503-PET for evaluating sigmal
receptor occupancy by neuroleptics: the binding of haloperidol to sigma1
and dopamine D2-like receptors. Ann Nucl Med 20: 569-573.
Kawamura K, Ishiwata K, Tajima H, Ishii S, Matsuno K, Homma Y, et
al. (2000). In vivo evaluation of [(11)C]SA4503 as a PET
ligand for mapping CNS sigma(1) receptors. Nucl Med Biol 27:255-261.
Lever JR, Gustafson JL, Xu R, Allmon RL, & Lever SZ (2006). Sigma-1 and
sigma-2 receptor binding affinity and selectivity of SA4503 and
fluoroethyl SA4503. Synapse 59: 350-358.
Mansur A, Rabiner EA, Comley RA, Lewis Y, Middleton LT, Huiban M,
et al. (2019). Characterization of 3 PET tracers for quantification of
mitochondrial and synaptic function in healthy human brain:
(18)F-BCPP-EF, (11)C-SA-4503, (11)C-UCB-J. J Nucl Med 61:96-103.
Matsuno K, Nakazawa M, Okamoto K, Kawashima Y, & Mita S (1996). Binding
properties of SA4503, a novel and selective sigma 1 receptor agonist.
Eur J Pharmacol 306: 271-279.
Morgan P, Van Der Graaf PH, Arrowsmith J, Feltner DE, Drummond KS,
Wegner CD, et al. (2012). Can the flow of medicines be improved?
Fundamental pharmacokinetic and pharmacological principles toward
improving Phase II survival. Drug Discov Today 17: 419-424.
Nieto FR, Cendan CM, Canizares FJ, Cubero MA, Vela JM, Fernandez-Segura
E, et al. (2014). Genetic inactivation and pharmacological
blockade of sigma-1 receptors prevent paclitaxel-induced sensory-nerve
mitochondrial abnormalities and neuropathic pain in mice. Mol Pain
10: 11.
Ortiz-Renteria M, Juarez-Contreras R, Gonzalez-Ramirez R, Islas LD,
Sierra-Ramirez F, Llorente I, et al. (2018). TRPV1 channels and
the progesterone receptor Sig-1R interact to regulate pain. Proc Natl
Acad Sci U S A 115: E1657-E1666.
Pabba M, Wong AY, Ahlskog N, Hristova E, Biscaro D, Nassrallah W,
et al. (2014). NMDA receptors are upregulated and trafficked to the
plasma membrane after sigma-1 receptor activation in the rat
hippocampus. J Neurosci 34: 11325-11338.
Romero L, Zamanillo D, Nadal X, Sanchez-Arroyos R, Rivera-Arconada I,
Dordal A, et al. (2012). Pharmacological properties of S1RA, a
new sigma-1 receptor antagonist that inhibits neuropathic pain and
activity-induced spinal sensitization. Br J Pharmacol 166:2289-2306.
Saif MW, & Reardon J (2005). Management of oxaliplatin-induced
peripheral neuropathy. Ther Clin Risk Manag 1: 249-258.
Sakata M, Kimura Y, Naganawa M, Oda K, Ishii K, Chihara K, et al.(2007). Mapping of human cerebral sigma1 receptors using positron
emission tomography and [11C]SA4503. Neuroimage 35: 1-8.
Sanchez-Fernandez C, Entrena JM, Baeyens JM, & Cobos EJ (2017). Sigma-1
receptor antagonists: A new class of neuromodulatory analgesics. Adv Exp
Med Biol 964: 109-132.
Stewart JM (2004). Chronic orthostatic intolerance and the postural
tachycardia syndrome (POTS). J Pediatr 145: 725-730.
Tziortzi AC, Searle GE, Tzimopoulou S, Salinas C, Beaver JD, Jenkinson
M, et al. (2011). Imaging dopamine receptors in humans with
[11C]-(+)-PHNO: dissection of D3 signal and anatomy. Neuroimage
54: 264-277.
Vela JM, Merlos M, & Almansa C (2015). Investigational sigma-1 receptor
antagonists for the treatment of pain. Expert Opin Investig Drugs
24: 883-896.
Zajaczkowska R, Kocot-Kepska M, Leppert W, Wrzosek A, Mika J, &
Wordliczek J (2019). Mechanisms of chemotherapy-induced peripheral
neuropathy. Int J Mol Sci 20: 1451.
Table 1: Pharmacokinetic–σ-1 brain receptor occupancy models